BiotechNews

Sarepta Therapeutics Faces Setback After Patient Death Linked to Gene Therapy Treatment

1 month ago

In a developing story within the biotech sector, Sarepta Therapeutics has seen a notable decline in its stock value following reports of a patient death associated with its gene therapy treatment. The company specializes in precision genetic medicine for rare diseases, notably Duchenne Muscular Dystrophy (DMD). This unexpected event has raised concerns among investors and regulators, prompting a thorough investigation.

Halozyme Retreats: A Surprising Withdrawal from Evotec Acquisition

5 months ago

In a significant shift within the pharmaceutical landscape, Halozyme Therapeutics has announced its decision to withdraw its bid to acquire the German drug developer, Evotec SE. The news was confirmed late last week, leaving many in the biotech sector pondering the implications of this sudden turnaround.

Halozyme Eyes Takeover Bid for Germany's Evotec: A New Era in Biotech Consolidation?

5 months ago

In a significant development in the global biotech landscape, Germany’s leading drug development firm, Evotec SE, has reportedly caught the attention of Halozyme Therapeutics Inc., an American company known for its innovative drug delivery technologies. This potential takeover could reshape the competitive dynamics within the industry, sparking speculation about future collaborations and growth trajectories.